R&D JP Morgan Week 2025 - Day 3 pharmaphorum's JPM Week live blog finishes strong with panels on AI, funding, and a conference wrap-up.
R&D JP Morgan Week 2025 - Day 2 On day 2 of pharmaphorum's JPM Week blog, we'll hear from leaders from the President of Novartis, a stacked industry panel on AI, and Dr Jill Biden.
News Lilly nets Scorpion cancer drug in $2.5bn licensing deal Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a breast cancer therapy being developed by Scorpion Therapeutics.
R&D JP Morgan Week 2025 - Day 1 On day 1 of JPM Week, join pharmaphorum as we hear about pharma's dealmaking plans and the changing pharma landscape.
News J&J agrees $14.6bn takeover of CNS biotech Intra-Cellular Johnson & Johnson has agreed to take over Intra-Cellular Therapies and its potential depression blockbuster Caplyta in a deal worth up to $14.6bn.
News GSK confirms plan to buy cancer firm IDRx for $1bn GSK confirms that it has agreed to buy US biotech IDRx and its KIT inhibitor for rare gastrointestinal tumours for $1bn upfront.
News NHS "isn't delivering equitable care for rare diseases" A Genetic Alliance UK report claims the NHS is failing to meet the needs of many of the 3.5 million people in the country who live with rare diseases.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
